Hjem › Hemofili B › Pennsylvania
Kliniske studier for Hemofili B i Pennsylvania
6 studier for Hemofili B søker deltakere på steder i Pennsylvania.
Byer i Pennsylvania
Offisiell studietekst (engelsk)
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia
RekruttererFase 3
Alder 18 og eldre · Menn · Oppdatert 2. okt. 2026 · NCT05568719A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- Children's Hospital of Philadelphia (CHOP), Philadelphia
RekruttererFase 1/2
Alder 2 og eldre · Menn · Oppdatert 11. sep. 2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Hemophilia Center of Western Pennsylvania (HCWP), Pittsburgh
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 27. aug. 2026 · NCT06003387ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Children's Hospital of Philadelphia, Philadelphia
- Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania, Philadelphia
- St. Christopher's Hospital for Children, Philadelphia
- og 1 flere
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- Penn State Milton S Hershey Medical Center Pediatrics, Hershey
- Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program, Philadelphia
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 60 · Alle kjønn · Oppdatert 2. jul. 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- The Feinstein Institutes for Medical Research, Philadelphia
RekruttererFase 3
Alder 1 til 74 · Menn · Oppdatert 1. jul. 2026 · NCT05145127Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.